1. Market Research
  2. > Pathology Industry

rheumatoid arthritis Industry, May 2016 Market Reports from Top Publishers

You might be interested in: Diagnostics, Disease Management, Diagnostic Test, Biosimilar, Pharmaceutical, Monoclonal Antibody, Stem Cell, Therapeutics, Therapy, Antibody, Clinical Trial, Company Sales Figures, Orthopedic Device, Sports Medicine.


 
1-10 of 71 reports for Rheumatoid Arthritis

Purchase Reports From Reputable Market Research Publishers

Global Rheumatoid Arthritis Partnering 2010 to 2016

Global Rheumatoid Arthritis Partnering 2010 to 2016

  • $ 1 495
  • Industry report
  • May 2016
  • by Currentpartnering

The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies. • ...

Rheumatoid Arthritis: KOL Insight

Rheumatoid Arthritis: KOL Insight

  • $ 8 085
  • Industry report
  • March 2016
  • by Firstword Pharma

Leading brands under threat as biosimilars and new pipeline drugs hit the market Key opinion leaders (KOLs) say Rheumatoid Arthritis (RA) treatment is in for a shakeup thanks to anti-TNF biosimilars, new ...

Foot Orthotic Insoles Market Analysis: By Type (Custom, Prefabricated); By End User (Sports (Running, Court); Medical (Diabetes, Rheumatoid Arthritis, Plantar Fasciitis, Metatarsalgia, Obesity); Comfort) -With Forecast (2015 - 2020)

Foot Orthotic Insoles Market Analysis: By Type (Custom, Prefabricated); By End User (Sports (Running, Court); Medical (Diabetes, Rheumatoid Arthritis, Plantar Fasciitis, Metatarsalgia, Obesity); Comfort) -With Forecast (2015 - 2020)

  • $ 5 250
  • Industry report
  • February 2016
  • by Industry ARC

Foot orthotic insoles are employed to correct the abnormalities associated with the foot. Foot orthotic insoles work by altering the biomechanics of the foot. The rise in geriatric population over the ...

Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2 000
  • Industry report
  • January 2016
  • by Delve Insight

SUMMARY DelveInsight’s Report, “Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, ...

Systemic Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Systemic Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2 000
  • Industry report
  • January 2016
  • by Delve Insight

SUMMARY DelveInsight’s Report, “Systemic Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed ...

Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2 000
  • Industry report
  • January 2016
  • by Delve Insight

SUMMARY DelveInsight’s Report, “Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug ...

 Juvenile Rheumatoid Arthritis-Pipeline Insights, 2016

Juvenile Rheumatoid Arthritis-Pipeline Insights, 2016

  • $ 1 250
  • Industry report
  • January 2016
  • by Delve Insight

SUMMARY DelveInsight’s, “ Juvenile Rheumatoid Arthritis-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Juvenile Rheumatoid ...

Rheumatoid Arthritis - Pipeline Review, H2 2015

Rheumatoid Arthritis - Pipeline Review, H2 2015

  • $ 2 500
  • Company report
  • December 2015
  • by Global Markets Direct

Rheumatoid Arthritis - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Rheumatoid Arthritis - Pipeline Review, H2 2015’, provides an overview of the Rheumatoid Arthritis’s therapeutic ...

NPS+ Rheumatoid Arthritis (EU5)

NPS+ Rheumatoid Arthritis (EU5)

  • $ 2 668
  • Industry report
  • December 2015
  • by Firstword Pharma

RA Drug Manufacturers: How Does Brand Loyalty Affect Your Market Share? Are European rheumatologists satisfied with the rheumatoid arthritis (RA) treatments on the market? How loyal are they to your brand? ...

NPS+ Rheumatoid Arthritis (US)

NPS+ Rheumatoid Arthritis (US)

  • $ 2 668
  • Industry report
  • December 2015
  • by Firstword Pharma

RA Drug Manufacturers: How Does Brand Loyalty Affect Your Market Share? Are US rheumatologists satisfied with the rheumatoid arthritis (RA) treatments on the market? How loyal are they to your brand? How ...

About 2 400 reports for Rheumatoid Arthritis

Download Unlimited Documents from Trusted Public Sources

Pathology Description

  • January 2014
    12 pages
  • Obesity  

    Arthritis  

View report >

Economic Analysis

January 2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.